Report Detail

Medical Devices & Consumables (Post-pandemic Era)-Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Research Report 2022

  • RnM4476215
  • |
  • 04 August, 2022
  • |
  • Global
  • |
  • 112 Pages
  • |
  • XYZResearch
  • |
  • Medical Devices & Consumables

Summary

The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.

2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.

According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.

Beijing Yanjing Bizhi Information Consulting Co., Ltd. (XYZResearch)released the 《(Post-pandemic Era)-Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Research Report 2022》, which aims to sort out the development status and trends of the Next-Generation Breast Cancer Diagnostic and Screening industry at home and abroad, estimate the overall market scale of the Next-Generation Breast Cancer Diagnostic and Screening industry and the market share of major countries, Next-Generation Breast Cancer Diagnostic and Screening industry, and study and judge the downstream market demand of Next-Generation Breast Cancer Diagnostic and Screening through systematic research, Analyze the competition pattern of Next-Generation Breast Cancer Diagnostic and Screening, so as to help solve the pain points of various stakeholders in Next-Generation Breast Cancer Diagnostic and Screening industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.

Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Next-Generation Breast Cancer Diagnostic and Screening Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Next-Generation Breast Cancer Diagnostic and Screening Market?
Abbott Laboratories
Agendia
Agilent Technologies
Ambry Genetics
Biocept
Biotheranostics
Centogene
Danaher Corporation
EXACT Sciences Corporation
Roche Holding AG
Fulgent Genetics
Illumina
Invitae
Lucence Diagnostics Pte Ltd
Myriad Genetics
Major Type of Next-Generation Breast Cancer Diagnostic and Screening Covered in XYZResearch report:
Real-Time PCR (q-PCR)
Immunohistochemistry (IHC)
Next-Generation Sequencing (NGS)
Fluorescent In-Situ Hybridization (FISH)
Application Segments Covered in XYZResearch Market
Hospital-associated Labs
Cancer Research Institutes
Diagnostic Centers

For any other requirements, please feel free to contact us and we will provide you customized report.


Table of Contents

    Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Research Report 2022

      1. Research Scope

        2. Market Overview

        • 2.1 Product Introduction, Application, Picture
        • 2.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market by Value
          • 2.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type
          • 2.2.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market by Value (%)
        • 2.3 Global Next-Generation Breast Cancer Diagnostic and Screening Market by Production
          • 2.3.1 Global Next-Generation Breast Cancer Diagnostic and Screening Production by Type
          • 2.3.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market by Production (%)

        3. The Major Driver of Next-Generation Breast Cancer Diagnostic and Screening Industry

        • 3.1 Historical & Forecast Global Next-Generation Breast Cancer Diagnostic and Screening Demand
        • 3.2 Largest Application for Next-Generation Breast Cancer Diagnostic and Screening (2018-2028)
        • 3.3 The Major Downstream Company in China Market 2022

        4. Global and Regional Next-Generation Breast Cancer Diagnostic and Screening Market

        • 4.1 Regional Market Size in Terms of Production & Demand (2022)
        • 4.2 Regional Market Share in Terms of Revenue (2018-2022)
        • 4.3 Concentration Ratio (CR5& CR10) of Next-Generation Breast Cancer Diagnostic and Screening Market
        • 4.4 Mergers & Acquisitions, Expansion Plans

        5. US Next-Generation Breast Cancer Diagnostic and Screening Production, Demand (2018-2028)

        • 5.1 Current and Estimated Production Breakdown by Type
        • 5.2 Current and Estimated Demand Breakdown by Type
        • 5.3 Current and Estimated Demand Breakdown by Application
        • 5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        6. Europe Next-Generation Breast Cancer Diagnostic and Screening Production, Demand (2018-2028)

        • 6.1 Current and Estimated Production Breakdown by Type
        • 6.2 Current and Estimated Demand Breakdown by Type
        • 6.3 Current and Estimated Demand Breakdown by Application
        • 6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        7. China Next-Generation Breast Cancer Diagnostic and Screening Production, Demand (2018-2028)

        • 7.1 Current and Estimated Production Breakdown by Type
        • 7.2 Current and Estimated Demand Breakdown by Type
        • 7.3 Current and Estimated Demand Breakdown by Application
        • 7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        8. Japan Next-Generation Breast Cancer Diagnostic and Screening Production, Demand (2018-2028)

        • 8.1 Current and Estimated Production Breakdown by Type
        • 8.2 Current and Estimated Demand Breakdown by Type
        • 8.3 Current and Estimated Demand Breakdown by Application
        • 8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        9. India Next-Generation Breast Cancer Diagnostic and Screening Production, Demand (2018-2028)

        • 9.1 Current and Estimated Production Breakdown by Type
        • 9.2 Current and Estimated Demand Breakdown by Type
        • 9.3 Current and Estimated Demand Breakdown by Application
        • 9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        10. Korea Next-Generation Breast Cancer Diagnostic and Screening Production, Demand (2018-2028)

        • 10.1 Current and Estimated Production Breakdown by Type
        • 10.2 Current and Estimated Demand Breakdown by Type
        • 10.3 Current and Estimated Demand Breakdown by Application
        • 10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        11. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Production, Demand (2018-2028)

        • 11.1 Current and Estimated Production Breakdown by Type
        • 11.2 Current and Estimated Demand Breakdown by Type
        • 11.3 Current and Estimated Demand Breakdown by Application
        • 11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        12. Global Next-Generation Breast Cancer Diagnostic and Screening Average Price Trend

        • 12.1 Market Price for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in US (2018-2022)
        • 12.2 Market Price for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in Europe (2018-2022)
        • 12.3 Market Price for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in China (2018-2022)
        • 12.4 Market Price for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in Japan (2018-2022)
        • 12.5 Market Price for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in India (2018-2022)
        • 12.6 Market Price for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in Korea (2018-2022)
        • 12.7 Market Price for Each Type of Next-Generation Breast Cancer Diagnostic and Screening in Southeast Asia (2018-2022)

        13. Industrial Chain (Impact of COVID-19)

        • 13.1 Next-Generation Breast Cancer Diagnostic and Screening Industrial Chain Analysis
        • 13.2 Downstream
        • 13.3 Impact of COVID-19
        • 13.4 Post-pandemic Era
        • 13.5 Technology Trends of Next-Generation Breast Cancer Diagnostic and Screening

        14. Next-Generation Breast Cancer Diagnostic and Screening Competitive Landscape

        • 14.1 Abbott Laboratories
          • 14.1.1 Abbott Laboratories Company Profiles
          • 14.1.2 Abbott Laboratories Product Introduction
          • 14.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
          • 14.1.4 Strategic initiatives
        • 14.2 Agendia
          • 14.2.1 Agendia Company Profiles
          • 14.2.2 Agendia Product Introduction
          • 14.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
          • 14.2.4 Strategic initiatives
        • 14.3 Agilent Technologies
          • 14.3.1 Agilent Technologies Company Profiles
          • 14.3.2 Agilent Technologies Product Introduction
          • 14.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
          • 14.3.4 Strategic initiatives
        • 14.4 Ambry Genetics
          • 14.4.1 Ambry Genetics Company Profiles
          • 14.4.2 Ambry Genetics Product Introduction
          • 14.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
          • 14.4.4 Strategic initiatives
        • 14.5 Biocept
          • 14.5.1 Biocept Company Profiles
          • 14.5.2 Biocept Product Introduction
          • 14.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
          • 14.5.4 Strategic initiatives
        • 14.6 Biotheranostics
          • 14.6.1 Biotheranostics Company Profiles
          • 14.6.2 Biotheranostics Product Introduction
          • 14.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
          • 14.6.4 Strategic initiatives
        • 14.7 Centogene
          • 14.7.1 Centogene Company Profiles
          • 14.7.2 Centogene Product Introduction
          • 14.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
          • 14.7.4 Strategic initiatives
        • 14.8 Danaher Corporation
          • 14.8.1 Danaher Corporation Company Profiles
          • 14.8.2 Danaher Corporation Product Introduction
          • 14.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
          • 14.8.4 Strategic initiatives
        • 14.9 EXACT Sciences Corporation
          • 14.9.1 EXACT Sciences Corporation Company Profiles
          • 14.9.2 EXACT Sciences Corporation Product Introduction
          • 14.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
          • 14.9.4 Strategic initiatives
        • 14.10 Roche Holding AG
          • 14.10.1 Roche Holding AG Company Profiles
          • 14.10.2 Roche Holding AG Product Introduction
          • 14.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Sales, Revenue (2018-2022)
          • 14.10.4 Strategic initiatives
        • 14.11 Fulgent Genetics
        • 14.12 Illumina
        • 14.13 Invitae
        • 14.14 Lucence Diagnostics Pte Ltd
        • 14.15 Myriad Genetics

        15. Conclusion

          16. Methodology and Data Source

          Summary:
          Get latest Market Research Reports on Next-Generation Breast Cancer Diagnostic and Screening. Industry analysis & Market Report on Next-Generation Breast Cancer Diagnostic and Screening is a syndicated market report, published as (Post-pandemic Era)-Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Research Report 2022. It is complete Research Study and Industry Analysis of Next-Generation Breast Cancer Diagnostic and Screening market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

          Last updated on

          REPORT YOU MIGHT BE INTERESTED

          Purchase this Report

          $2,850.00
          $5,700.00
          2,348.40
          4,696.80
          2,775.90
          5,551.80
          380,503.50
          761,007.00
          226,888.50
          453,777.00
          Credit card Logo

          Related Reports


          Reason to Buy

          Request for Sample of this report